文献速递前列腺癌

磁共振成像分层临床路径与系统性经直肠超声引导活检路径检测临床显著前列腺癌的比较:随机对照试验的系统综述与Meta分析

Comparison of Magnetic Resonance Imaging-stratified Clinical Pathways and Systematic Transrectal Ultrasound-guided Biopsy Pathway for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
PubMed 文献 · Eur Urol Oncol · 2019-06-14

该系统综述与Meta分析纳入9项随机对照试验共2908例疑似前列腺癌患者,比较磁共振成像分层路径与系统性经直肠超声引导活检路径的临床显著前列腺癌检出率。结果显示磁共振成像分层路径检出更多临床显著前列腺癌(相对检出率1.45,95%CI 1.09-1.92),在初次活检和既往活检阴性患者中均如此;临床不显著前列腺癌检出率无显著差异(0.89,95%CI 0.49-1.62),任何前列腺癌检出率更高(1.39,95%CI 1.05-1.84)。

要点

  • 磁共振成像分层路径检出临床显著前列腺癌的相对检出率为1.45(95%CI 1.09-1.92)。
  • 初次活检患者相对检出率1.42(95%CI 1.02-1.97),既往活检阴性患者1.60(95%CI 1.01-2.54)。
  • 临床不显著前列腺癌检出率无显著差异(0.89,95%CI 0.49-1.62)。

核心结论

  • 在临床疑似前列腺癌的男性中,磁共振成像分层路径检出的临床显著前列腺癌多于系统性经直肠超声引导活检路径,初次活检和既往活检阴性患者均如此。
  • 磁共振成像分层路径的任何前列腺癌检出率更高,但临床不显著前列腺癌检出率与系统性经直肠超声引导活检路径无显著差异。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、EMBASE和Cochrane数据库至2019年3月18日,纳入报告两种路径临床显著前列腺癌检出率的随机对照试验,共9项随机对照试验2908例患者。
  • 使用随机效应模型合并磁共振成像分层路径的相对临床显著前列腺癌检出率,采用Cochrane随机试验偏倚风险工具评估研究质量。

主要发现

  • 磁共振成像分层路径检测临床显著前列腺癌的相对检出率为1.45(95%CI 1.09-1.92)。
  • 初次活检患者相对检出率为1.42(95%CI 1.02-1.97),既往活检阴性患者为1.60(95%CI 1.01-2.54)。
  • 临床不显著前列腺癌的相对检出率为0.89(95%CI 0.49-1.62),两种路径间无显著差异。
  • 任何前列腺癌的相对检出率为1.39(95%CI 1.05-1.84),磁共振成像分层路径更高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Recent studies suggested that magnetic resonance imaging (MRI) followed by targeted biopsy ("MRI-stratified pathway") detects more clinically significant prostate cancers (csPCa) than the systematic transrectal ultrasound-guided prostate biopsy (TRUS-Bx) pathway, but controversy persists. Several randomized clinical trials (RCTs) were recently published, enabling generation of higher-level evidence to evaluate this hypothesis. OBJECTIVE: To perform a systematic review and meta-analysis of RCTs comparing the detection rates of csPCa in the MRI-stratified pathway and the systematic TRUS-Bx pathway in patients with a suspicion of prostate cancer (PCa). EVIDENCE ACQUISITION: PubMed, EMBASE, and Cochrane databases were searched up to March 18, 2019. RCTs reporting csPCa detection rates of both pathways in patients with a clinical suspicion of prostate cancer were included. Relative csPCa detection rates of the MRI-stratified pathway were pooled using random-effect model. Study quality was assessed using the Cochrane risk of bias tool for randomized trials. A comparison of detection rates of clinically insignificant PCa (cisPCa) and any PCa was also performed. EVIDENCE SYNTHESIS: Nine RCTs (2908 patients) were included. The MRI-stratified pathway detected more csPCa than the TRUS-Bx pathway (relative detection rate 1.45 [95% confidence interval {CI} 1.09-1.92] for all patients, and 1.42 [95% CI 1.02-1.97] and 1.60 [95% CI 1.01-2.54] for biopsy-naïve and prior negative biopsy patients, respectively). Detection rates were not significantly different between pathways for cisPCa (0.89 [95% CI 0.49-1.62]), but higher in the MRI-stratified pathway for the detection of any PCa (1.39 [95% CI 1.05-1.84]). CONCLUSIONS: The MRI-stratified pathway detected more csPCa than the systematic TRUS-guided biopsy pathway in men with a clinical suspicion of PCa, for both biopsy-naïve patients and those with prior negative biopsy. The detection rate of any PCa was higher in the MRI-stratified pathway, but not significantly different from that of cisPCa. PATIENT SUMMARY: Our meta-analysis of clinical trials shows that the magnetic resonance imaging-stratified pathway detects more clinically significant prostate cancers than the transrectal ultrasound-guided prostate biopsy pathway in men with a suspicion of prostate cancer.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Woo S, Suh CH, Eastham JA, et al. Comparison of Magnetic Resonance Imaging-stratified Clinical Pathways and Systematic Transrectal Ultrasound-guided Biopsy Pathway for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Eur Urol Oncol. 2019. PMID: 31204311. doi:10.1016/j.euo.2019.05.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。